This trial is trying to understand how safe, well tolerated and effective a new targeted cancer drug is in patients with squamous cell carcinoma of the head and neck, non-small cell lung cancer or colorectal cancer.
This trial is treating multiple types of cancer including squamous cell carcinoma of the head and neck, non-small cell lung cancer or colorectal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Eligible patients will receive MVC-101, across either a dose escalation or cohort expansion phase.
Recruiting Hospitals Read More